NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced record third quarter r... Read more
Reduces workforce by roughly 40%; expects annualized cost savings of more than $35 million Discontinues development of therapeutics division and commences strategic alternatives process for all in-house therapeutic programs 23andMe Holding Co. , ... Read more
With a renewed focus on drug prices, fast-track approvals, and ‘America First’ production, industry experts warn pharma to brace for Trump’s second act – where ‘Big Pharma’ meets ‘Big Savings’ (... Read more
Financial report for the period 1 January 2024 to 30 September 2024 ... Read more
BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Biotheus (“Biotheus”) announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery... Read more
Financial report for the period 1 January 2024 to 30 September 2024 ... Read more
" Ardena, a leading CDMO, has received full GMP approval for its advanced nanomedicine facility in Oss. This €20 million investment, featuring state-of-the-art cleanrooms and automated manufacturing flows, equips Ardena to deliver high-quality... Read more
" Abzena, a leading CDMO/CRO, now offers GMP cell-based potency assays at its UK and US sites, enhancing its support for complex biologics and ADC programs. The expanded analytical toolkit enables faster, reliable data on drug potency, MOA, and stabi... Read more
© 2024 Biopharma Boardroom. All Rights Reserved.
